Key Insights

Highlights

Treatment Research

5 treatments under study, led by Cisplatin

Research Leaders

5 sponsors active, led by Karolinska University Hospital

Related Conditions

Often studied with 19 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
Phase 1 (1)
Phase 1/2 (2)

Trial Status

Terminated1
Unknown1
Recruiting1

Clinical Trials (3)

Showing 3 of 3 trials
NCT05498597Phase 1Unknown

AMT-151 in Patients With Selected Advanced Solid Tumours

NCT00794417Phase 1/2TerminatedPrimary

A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced Carcinoma

SYF627a4e4ac80e43a08078baf6deac3dffPhase 1/2Recruiting

Sodium selenite in patients with advanced carcinoma: SECAR 1c

Showing all 3 trials

Research Network

Common Treatments

  • Cisplatin1
  • Pemetrexed1
  • Sodium Selenite Pentahydrate1
  • Aflibercept1
  • Amt1511

Active Sponsors

  • Karolinska University Hospital1
  • Multitude Therapeutics Inc.1
  • Regeneron Pharmaceuticals, Inc.1
  • Sanofi1
  • Tigermed Consulting Co., Ltd1

Top Investigators

Related Conditions

  • Nonsmall Cell Lung Cancer1
  • Ovarian Clear Cell Carcinoma1
  • Ovarian Mucinous Adenocarcinoma1
  • Ovarian Carcinoma1
  • Ovarian Endometrioid Adenocarcinoma1

Activity Timeline